Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-08-14
2007-08-14
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100, C424S199100, C424S232100
Reexamination Certificate
active
08746668
ABSTRACT:
Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodeficiency virus epitope such as an antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinants can be NYVAC or ALVAC recombinants. The DNA can encode at least one of: Env, Gag, Pol, or combinations thereof such as Gag and Pol or protease or Env, Gag and Pol or protease. The recombinants and gene products therefrom and antibodies generated by them have several preventive, therapeutic and diagnostic uses. DNA from the recombinants are useful as probes or, for generating PCR primers or for immunization. The immunogenicity and protective efficacy of immunization protocols involving ALVAC-FIV and priming with a recombinant canarypox virus ALVAC-FIV vaccine followed by a booster immunization with inactivated FIV-infected celled vaccine (ICV) was evaluated against FIV challenge in cats and the protocol was shown to effectively induce FIV-specific protective immune responses. Further, it was found that immunized cats were fully protected from an initial challenge with a slightly heterologous FIV strain (50CID50) and were partially protected from a second challenge with a distinctly heterologous FIV strain (75CID50) given eight months after the initial challenge without any intervening booster.
REFERENCES:
patent: 5275813 (1994-01-01), Yamamoto et al.
patent: 5413927 (1995-05-01), Tompkins et al.
patent: 5736378 (1998-04-01), Elder et al.
patent: 5756103 (1998-05-01), Paoletti et al.
patent: 5766598 (1998-06-01), Paoletti et al.
patent: 5863542 (1999-01-01), Paoletti et al.
patent: 9530019 (1995-11-01), None
Cox, W. I., et al., 1993, “Induction of Cytotoxic T Lymphocytes by Recombinant Canarypox (ALVAC) and Attenuated Vaccinia (NYVAC) Viruses Expressing the HIV-1 Envelope Glycoprotein”, Virol. 195:845-850.
Verschoor, E.J., et al., 1993, “Expression of Feline Immunodeficiency VirusgagandenvPrecursor Proteins inSpodoptera frugiperdaCells and Their Use in Immunodiagnosis”, J. Clin. Microbiol. 31(9):2350-2355.
Lutz, H., et al., 1995, “FIV Vaccine Studies. I. Immune response to recombinant FIVenvgene products and outcome after challenge infection”, Vet. Immunol. Immunopath. 46:103-113.
Pialoux, G., et al., 1995, “A Prime-Boost Approach to HIV Preventative Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)”, AIDS Res. Human Retrovir. 11(3):373-381.
Talbott, R. L., et al., 1989, “Nucleotide sequence and genomic organization of feline immunodeficiency virus”, Proc. Natl. Acad. Sci. USA 86(15):5743-5747.
Maki, N., et al., 1992, “Molecular characterization and heterogeneity of feline immunodeficiency virus isolates”, Arch. Virol. 123(1-2):29-45.
Miyazawa, T., et al., 1994, “The genome of feline immunodeficiency virus”, Arch. Virol. 134(3-4):221-234.
Tartaglia, J., et al., 1993, “Protection of Cats against Feline Leukemia Virus by Vaccination with a Canarypox Virus Recombinant, ALVAC-FL”, J. Virol. 67(4):23702375.
Abimiku, A., Franchini, G., Tartaglia, J. Aldrich, K., Myagkikh, M., Markham, P.D., Chong, P., Klein, M., Kieny, M.P., Paoletti, E., Gallo, R.C., and Guroff, M.R., Nature Medicine 1, 321-329 (1995).
Altenburger, W., C-P. Suter and J. Altenburger, Archives Virol. 105, 15-27 (1989).
Behbehani, A.M., Microbiological Reviews 47, 455-509 (1983).
Bergoin, M., and Dales, S., In Comparative Virology, eds. K. Maramorosch and E. Kurstak, (Academic Press, NY) pp. 169-205 (1971).
Berman, P., Gregory, T., Riddle, L., Nakamura, G., Champe, M., Porter, J., Wurm, F., Hershberg, R., Cobb, E. and Eichberg, J., Nature 345, 622-625 (1990).
Bocchia, M. et al., Blood 85, 2680-2684.
Buller, R.M.L., G.L. Smith, Cremer, K., Notkins, A.L., and Moss, B., Nature 317, 813-815 (1985).
Cadoz, M., A. Strady, B. Meignier, J. Taylor, J. Tartaglia, E. Paoletti and S. Plotkin, The Lancet, 339, 1429-1432 (1992).
Child, S.J., Palumbo, G.J., Buller, R.M.L., and Hruby, D.E. Virology 174, 625-629 (1990).
Clements, M.L., Weinhold, K., Siliciano, R., Schwartz, D., Matthews, T., Graham, B., Keefer, M., McElrath, J., Gorse, G., Hsieh, R., Duliege, A.M., Excler, J., Meignier, B., Tartaglia, J., and Paoletti, E., HIV immunity induced by carnarypox (ALVAC)-MN gl160, -SF-2, rgp120 or both. XI International Conference on AIDS/Vancover 1996/Mo.A.281 (1996).
Clewell, D.B. and D.R. Helinski, Proc. Natl. Acad. Sci. USA 62, 1159-1166 (1969).
Clewell, D.B., J. Bacteriol 110, 667-676 (1972).
Cox, W.I., Tartaglia, J., and E. Paoletti. Virology 195, 845-850 (1993).
Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K., and Descssers, R., Science 258, 1938-1941 (1992).
Drillien et al., Virology 111, 488-499 (1981).
Edbauer, C., R. Weinberg, J. Taylor, A., Rey-Senelonge, J.F. Bouquet, P. Desmettre, and E. Paoletti, Virology 179, 901-904 (1990).
Eldridge, J.H., et al., Current Topics in Microbiology and Immunology, 146:59-66 (1989).
Emini, E., Schleif, W., Nunberg, J., Conley, A., Eda, Y., Tokiyoshi, S., Putney, S., Matsushita, S., Cobb, K., Jett, C., Eichberg, J., and K. Murthy, Nature 355, 728-730 (1992).
Engelke, D.R., Hoener, P.A., and Collins, F.S., Proc. Natl. Acad. Sci. USA 85, 544-548 (1988).
Englehard, V.H., Ann. Rev. Immunol. 12:181 (1994).
Franchini, G., Tartaglia, J., Markham, P., Benson, J., Fullen, J., Wills, M., Arp, J., Dekaban, G., Paoletti, E., and Gallo, R.C., AIDS Res. Hum. Retroviruses 11, 307-313 (1995).
Francini, G. Guroff, M.R. Tartaglia, J., Aggarwal, A., Abimiku, A., Benson, J., Markham, P., Limbach, K., Hurteau, G., Fullen, J., Aldrich, K., Miller, N., Sadoff, J., Paoletti, E., and Gallo, R.C., AIDS Res. Hum. Retroviruses 11, 909-920 (1995).
Fries et al., 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA (Oct. 1992).
Fries, L.F., Tartaglia, J., Taylor, J., Kauffman, E. K., Meignier, B., Paoletti, E., and Plotkin, S., Vaccine 14, 428-434 (1996).
Fultz, P., Nara, P., Barre-Sinoussi, F., Chaput, A., Greenberg, M., Muchmore, E., Kieny, M.-P and Girard, M. Science 256, 1687-1689 (1992).
Funahashi, S., T. Sato and H. Shida, J. Gen. Virol. 69, 35-47 (1988).
Gillard, S., Spehner, D., Drillien, R., and Kirn, A., Proc. Natl. Acad. Sci. USA 83, 5573-5577 (1986).
Girard, M., Kieny, M.-P., Pinter, A., Barre-Sinoussi, F., Nara, P., Kolbe, H., Kusui, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczorek, M., Gomard, E., Gluckman, J.-C. and Fultz, P., Proc. Natl. Acad. Sci. USA 88, 542-546 (1991).
Goebel, S.J., G.P. Johnson, M.E. Perkus, S.W. Davis, J.P. Winslow and E. Paoletti, Virology 179, 247-266 (1990b).
Goebel, S.J., Johnson, G.P., Perkus, M.E., Davis, S.W., Winslow, J.P., Paoletti, E., Virology 179, 247-266 (1990a).
Goldstein, D.J. and S.K. Weller, Virology 166, 41-51 (1988).
Goodman-Snitoff et al., J. Immunol. 147:410-415 (1991).
Guo, P., Goebel, S., Davis, S., Perkus, M.E., Languet, B., Desmettre, P., Allen, G., and Paoletti, E., J. Virol. 63, 4189-4198 (1989).
Guo et al., J. Virol. 64, 2399-2406 (1990).
Hardy, Jr., W.D. in Retrovirus Biology and Human Disease, Gallo, R.C. and Wong-Staal, eds., Marcel Dekker, New York, pp. 33-86, 1990.
Heeney, J.L., Holterman, L., ten Hoaft, P., et al., AIDS Res. Human. Retrovir. 10 Suppl. 2, S117-S121 (1994).
Hoise, M.J., Osborne, R. Yamamoto, J.K., Neil, J.C., and Jarrett, O. J. Virol. 69, 1253-1255 (1995).
Hruby, D.E. and L.A. Ball, J. Virol. 43, 403-409 (1982).
Hruby, D.E., R.A. Maki, D.B. Miller and L.A. Ball, Proc. Natl. Acad. Sci. USA 80, 3411-3415 (1983).
Hu, S.-L, Polacino, P., Klaniecki, J., Travis, B., Wrey, T., Pennathur, S., Stallard, V., Kornas, H., Langlois, A.J., and Benveniste, R.E. (1995) AIDS Research and Human Retroviruses 11:5136.
Hu, S.-L
Paoletti Enzo
Tartaglia James
Connaught Technology Corporation
Frommer & Lawrence & Haug LLP
Jarecki-Black Judy
Kowalski Thomas J.
Parkin Jeffrey S.
LandOfFree
ALVAC/FIV constructs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ALVAC/FIV constructs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ALVAC/FIV constructs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3843369